Figure 1
Figure 2
Figure 3
Clinicopathological characteristics of the gastric cancer patients
| Clinicopathological characteristic | All patients | Surgery only | Perioperative and adjuvant treatment | P |
|---|---|---|---|---|
| (n = 482) | (n = 241) | (n = 241) | ||
| Age [years ± SD] | 62.2 ± 11.2 | 62.02 ± 12.3 | 62.35 ± 9.9 | NS |
| Gender [n(%)] | NS | |||
| Male | 322 (66.8) | 153 (63.5) | 169 (70.1) | |
| Female | 160 (33.2) | 88 (36.5) | 72 (29.9) | |
| Capecitabine 111(46) | ||||
| EOX 91(37.7) | ||||
| XELOX 16(6.6) | ||||
| Type of chemotherapy [n (%)]* | 5FUCP 19(7.9) | |||
| 5FULV 3(1.2) | ||||
| Paclitaxel+CP 1(0.4) | ||||
| Tumor site | ||||
| Distal third | 151 (31.3) | 75 (31.1) | 76 (31.5) | |
| Middle third | 226 (46.9) | 113 (46.9) | 113 (46.9) | NS |
| Proximal third | 85 (17.6) | 38 (15.8) | 47 (19.5) | |
| Whole stomach | 11 (2.3) | 7 (2.9) | 4 (1.7) | |
| Stump | 9 (1.9) | 8 (3.3) | 1 (0.4) | |
| ASA score [n (%)] | 0.044 | |||
| I | 188 (39) | 90 (37.3) | 98 (40.7) | |
| II | 239 (49.6) | 113 (46.9) | 126 (52.3) | |
| III | 55 (11.4) | 38 (15.8) | 17 (7.1) | |
| T stage [n (%)] | NS | |||
| T0 | 6 (1.2) | 2 (0.8) | 4 (1.7) | |
| T1 | 62 (12.9) | 36 (14.9) | 26 (10.8) | |
| T2 | 75 (15.6) | 35 (14.5) | 40 (16.6) | |
| T3 | 266 (55.2) | 138 (57.3) | 128 (53.1) | |
| T4 | 73 (15.1) | 30 (12.4) | 43 (17.8) | |
| N stage [n (%)] | NS | |||
| N0 | 158 (32.8) | 86 (35.7) | 72 (29.9) | |
| N1 | 82 (17) | 31 (12.9) | 51 (21.2) | |
| N2 | 97 (20.1) | 42 (17.4) | 55 (22.8) | |
| N3a | 89 (18.5) | 53 (22) | 36 (14.9) | |
| N3b | 56 (11.6) | 29 (12) | 27 (11.2) | |
| UICC stage [n (%)] | ||||
| 0 | 8 (8) | 1 (0.4) | 3 (1.2) | |
| Ia | 54 (11.2) | 35 (14.5) | 19 (7.9) | |
| Ib | 35 (7.3) | 16 (6.6) | 19 (7.9) | |
| IIa | 73 (15.1) | 36 (14.9) | 37 (15.4) | |
| IIb | 83 (17.2) | 30 (12.4) | 53 (22) | NS |
| IIc | 2 (0.4) | 2 (0.8) | 0 (0) | |
| IIIa | 94 (19.5) | 44 (18.3) | 50 (20.7) | |
| IIIb | 79 (16.4) | 47 (19.5) | 32 (13.3) | |
| IIIc | 57 (11.8) | 30 (12.4) | 27 (11.2) | |
| IV | 1 (0.2) | 0 (0) | 1 (0.4) | |
| Clavien-Dindo classification [n (%)] | ||||
| 0 | 388 (80.5) | 197 (81.7) | 191 (79.3) | NS |
| I | 0 (0.0) | 0 (0) | 0 (0) | |
| II | 44 (9.1) | 14 (5.8) | 30 (12.4) | |
| IIIa | 10 (2.1) | 3 (1.2) | 7 (2.9) | |
| IIIb | 27 (5.6) | 16 (6.6) | 11 (4.6) | |
| IV | 0 (0) | 0 (0) | 0 (0) | |
| V | 13 (2.7) | 11 (4.6) | 2 (0.8) | |
| Number of extracted LNs [n ± SD] | 25.6 ± 13.1 | 24.9 ± 13.5 | 26.3 ± 12.6 | NS |
| Number of positive LNs [n ± SD] | 6.2 ± 9.3 | 6.8 ± 10.5 | 5.6 ± 8 | NS |
| Tumour [mm ± SD] diameter | 59.4 ± 35.8 | 61.4 ± 38.6 | 57.6 ± 33.3 | NS |
| CEA [μg/l ± SD] | 5 ± 14.5 | 4.25 ± 10.9 | 5.7 ± 16.9 | NS |
| CA 19-9 [μU/l ± SD] | 135.1 ± 799.5 | 66.8 ± 287.8 | 189.9 ± 1037.3 | NS |
| Perioperative morbidity [%] | 9 (33.3) | 2 (28.6) | 7 (35) | NS |
| Mortality [%] | 0 (0) | 0 (0) | 0 (0) | NS |
Predictors of survival
| Significance | HR | 95.0% CI for HR | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Age | 0.000 | 1.024 | 1.011 | 1.037 |
| CA 19-9 | 0.016 | 1.000 | 1.000 | 1.000 |
| UICC stage | 0.000 | 2.147 | 1.677 | 2.748 |
| Positive lymph nodes | 0.000 | 1.030 | 1.017 | 1.044 |
| Perioperative therapy | 0.032 | 0.741 | 0.563 | 0.975 |
Recorded reccurence patterns for T and N stage
| Peritoneal carcinomatosis [n (%)] | Haemathogenous spread [n (%)] | P | |
|---|---|---|---|
| T stage | |||
| T1 | 0 (0) | 0 (0) | |
| T2 | 1 (8.3) | 4 (36.4) | 0.019 |
| T3 | 5 (41.7) | 6 (54.5) | |
| T4 | 6 (50) | 1 (9.1) | |
| N stage | |||
| N0 | 2 (16.7) | 1 (9.1) | |
| N1 | 1 (8.3) | 2 (18.2) | |
| N2 | 3 (25) | 6 (54.5) | NS |
| N3a | 4 (33.3) | 1 (9.1) | |
| N3b | 2 (16.7) | 1 (9.1) |